The Promise of Romidepsin

March/April 2013

As mentioned earlier in this issue of TreatmentUpdate, the anti-cancer drug romidepsin (Istodax) can also inhibit the activity of HDAC (histone deacetylase), an enzyme that can help keep HIV infection latent.

Researchers with the pharmaceutical company Gilead Sciences performed laboratory experiments with cells extracted from 46 HIV-positive ART users whose CD4+ counts were above 350 cells and viral load less than 50 copies/ml. Specifically the researchers tested the following HDAC inhibitors:

  • romidepsin
  • panobinostat
  • givinostat
  • vorinostat
  • mocetinostat

Romidepsin appeared to be the most potent HDAC inhibitor in these test-tube studies. Its ability to bring HIV out of latency was consistent over time with cells from the same or different donors.

Regulatory authorities in the U.S. have approved the use of romidepsin, given intravenously at a dose of 15 mg per square metre of skin surface, for the treatment of certain cancers. However, according to the Gilead experiments, much lower doses can be used when attempting to bring HIV out of latency. These lower doses range between 2 and 5 mg/m2.

Based on these promising but preliminary experiments, expect a clinical trial of romidepsin in the future.


  1. Kent SJ, Reece JC, Petravic J, et al. The search for an HIV cure: tackling latent infection. Lancet Infectious Diseases. 2013; in press.
  2. Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013; in press.
  3. Wei G, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces HIV in resting CD4+ T cells from ART-suppressed subjects at concentrations achieved by clinical dosing. In: Program and abstracts of the 20th Conference on Retroviruses and Opportunistic Infections, 3-6 March 2013, Atlanta, U.S. Abstract 376.

This article was provided by Canadian AIDS Treatment Information Exchange. It is a part of the publication TreatmentUpdate. Visit CATIE's Web site to find out more about their activities, publications and services.
See Also
No Proof of New HIV Cure, Despite Headlines -- Here's What We Know
The Only Cases of HIV Cure or Remission
Beyond the Berlin Patient: How Researchers Are Now Trying to Cure More HIV-Positive People (Video)
What Would an HIV Cure Mean for You?

No comments have been made.

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read's Comment Policy.)

Your Name:

Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.